Please ensure Javascript is enabled for purposes of website accessibility

Why Shares of Fulgent Genetics Fell 20% in April

By Jason Hawthorne - May 5, 2021 at 1:28PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Good news for the U.S. has been bad news for shareholders.

What happened

Shares of genetic testing company Fulgent Genetics (FLGT 0.92%) fell 20% in April, according to data from S&P Global Market Intelligence.

Although that is up 475% from the beginning of 2020, the drop leaves the stock down 60% from its highs in February.

A COVID testing drive up location with cars lined up and an orange and white sign with an arrow pointing to the line.

Image source: Getty Images.

So what

The success in rolling out COVID-19 vaccines has been the driver of Fulgent's continued sell-off this past month. In the fourth quarter, nearly 90% of revenue came from COVID-19 testing as opposed to Fulgent's core genetic testing. The distribution of vaccines and declining cases have resulted in about half the rate of testing compared to the beginning of the year. That's spooked investors who saw the company's volume grow to 3.2 million billable tests last year -- 230 times more than in 2019. 

If COVID-19 testing does dissipate, that would leave shareholders with a growing, albeit smaller, business. Projected over a full year, its $37 million in core testing for the fourth quarter would leave the company trading at roughly 14 times sales. That's about twice as high as it entered 2020. Admittedly, COVID-19 isn't going away tomorrow. That said, investors aren't going to buy the stock if they think 90% of sales are drying up.

What now

Fulgent reports earnings on May 6, and the stock may trade violently whether Wall Street interprets the update as positive or negative. The uncertainty surrounding how well COVID-19 testing is holding up, and whether core genetic testing can pick up any slack, creates a scenario where a large group of people will be surprised no matter what the company says.

Although vaccinations are going well, the company has agreements with several local governments, major companies, and school systems. That should create a soft landing for the COVID-19 business over the next year or two. Also, Fulgent's legacy business grew 43% in the fourth quarter -- fast enough to justify the current stock price as long as some COVID-19 testing persists.

Jason Hawthorne has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Fulgent Genetics, Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Fulgent Genetics, Inc. Stock Quote
Fulgent Genetics, Inc.
FLGT
$52.69 (0.92%) $0.48

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
390%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.